Diclofenac Potassium With Lidocaine Cream in Reducing Pain During HSG

Model scores of the 29,894 trials active now.

Model score 6% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: to determinepatientstudy isdetermine thetrial of
  Phrases that lowered it: the aimaim ofthe efficacytrialcream
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Minimum age: 19 (lowers risk) · Who can join
• Has a data monitoring committee: Yes (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Drug's FAERS reports with a death: 9.4% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Trials the sponsor started in the prior 2 years: 97 (lowers risk) · Sponsor's track record
• Responsible party: principal investigator (lowers risk) · Design
• Drug's FAERS reports marked serious: 69.9% (lowers risk) · Drug's FDA history
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: parallel (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 13284 (lowers risk) · Drug's FDA history
• Blinding: double (raises risk) · Design
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 49 (lowers risk) · Sponsor's track record
• Disease area, neurology: No (lowers risk) · Disease area

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Lidocaine-prilocaine Cream on IUD Insertion Pain NCT02658773 · started 2016 · scored riskier than 8% of active trials completed
• Self-administered Lidocaine Gel for Pain-control During Cervical Preparation for Dilation and Evacuation NCT02852434 · started 2016 · scored riskier than 13% of active trials completed
• A Study to Assess the Efficacy and Tolerability of Diclofenac Potassium Soft Gelatin Capsules Compared With Ibuprofen Tablets in Patients With Moderate to Severe Postoperative Dental Pain NCT02476422 · started 2015 · scored riskier than 19% of active trials completed
• Diclofenac Plus Lidocaine Gel for Pain Relief During Intrauterine Device Insertion(IUD). NCT02332057 · started 2015 · scored riskier than 14% of active trials completed
• Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Compared to Placebo in Subjects With Acute Blunt Trauma Injuries NCT02290821 · started 2014 · scored riskier than 7% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.